PMID- 37747440
OWN - NLM
STAT- MEDLINE
DCOM- 20240426
LR  - 20240426
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
VI  - 33
IP  - 4
DP  - 2024 Apr
TI  - Clinical efficacy of conbercept injection on neovascular age-related macular 
      degeneration under different levels of inflammation.
PG  - 335-342
LID - 10.17219/acem/168808 [doi]
AB  - BACKGROUND: Age-related macular degeneration (AMD) is considered one of the most 
      common causes of irreversible blindness among elderly patients. Neovascular AMD, 
      which accounts for 10% of all AMD cases, can cause devastating vision loss due to 
      choroidal neovascularization (CNV). The clinical effects and safety of 
      intravitreal injection of conbercept in patients suffering from neovascular AMD 
      have not been fully evaluated. OBJECTIVES: The aim of the study was to evaluate 
      the efficacy and safety of intravitreal injection of conbercept in patients with 
      neovascular AMD with different levels of inflammation. MATERIAL AND METHODS: A 
      total of 120 consecutive patients with neovascular AMD who underwent intravitreal 
      injection of conbercept (3 injections per month + pro re nata (3 + PRN)) were 
      included and stratified based on the intraocular level of high-sensitivity 
      C-reactive protein (hs-CRP). The level of inflammation was defined as low, medium 
      or high, based on the concentration of hs-CRP prior to injection. Before and 
      after conbercept injections, best-corrected visual acuity (BCVA) and central 
      retinal thickness (CRT) were compared, respectively. Moreover, cytokine markers 
      as well as the frequency of injections and adverse events (AEs) were measured. 
      RESULTS: There were significant differences in BCVA and CRT between low, medium 
      and high tertiles. Compared to the baseline, improved BCVA was observed, and CRT 
      declined significantly after operation. Adverse events were most observed in high 
      tertiles. A significant decrease in vascular endothelial growth factor (VEGF), 
      interleukin (IL)-6 and IL-8 was observed after 1 year. CONCLUSIONS: The 
      effectiveness of conbercept on neovascular AMD varies depending on the level of 
      inflammation, which could be achieved by administering different injection 
      frequencies at different levels of inflammation. Furthermore, conbercept is 
      associated with the reduction of inflammatory factor (IL-6 and IL-8) levels after 
      intravitreal injection, which suggests that suppressing inflammatory response 
      might contribute to the clinical efficacy of anti-VEGF treatment. Our results 
      provide a novel mechanism for conbercept in patients with neovascular AMD.
FAU - Zhang, Xinyue
AU  - Zhang X
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
AD  - Department of Ophthalmology, Shengjing Hospital of China Medical University, 
      Shenyang, China.
FAU - Zhuang, Xiaotong
AU  - Zhuang X
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
FAU - Dong, Jie
AU  - Dong J
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
FAU - Fu, Bo
AU  - Fu B
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
FAU - Zhang, Genghua
AU  - Zhang G
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
FAU - Xu, Li
AU  - Xu L
AD  - Department of Ophthalmology, Fourth People's Hospital of Shenyang, China.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
RN  - 1P05PW62F3 (KH902 fusion protein)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Recombinant Fusion Proteins/administration & dosage/adverse effects
MH  - Female
MH  - Aged
MH  - *Intravitreal Injections
MH  - *Inflammation/drug therapy
MH  - *Macular Degeneration/drug therapy
MH  - Treatment Outcome
MH  - Aged, 80 and over
MH  - Visual Acuity/drug effects
MH  - Choroidal Neovascularization/drug therapy
MH  - C-Reactive Protein/analysis/metabolism
MH  - Middle Aged
MH  - Angiogenesis Inhibitors/administration & dosage/adverse effects
OTO - NOTNLM
OT  - age-related macular degeneration
OT  - conbercept
OT  - hs-CRP
OT  - inflammation
OT  - intravitreal injection
EDAT- 2023/09/25 12:41
MHDA- 2024/04/26 18:53
CRDT- 2023/09/25 10:52
PHST- 2022/09/05 00:00 [received]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2024/04/26 18:53 [medline]
PHST- 2023/09/25 12:41 [pubmed]
PHST- 2023/09/25 10:52 [entrez]
AID - 10.17219/acem/168808 [doi]
PST - ppublish
SO  - Adv Clin Exp Med. 2024 Apr;33(4):335-342. doi: 10.17219/acem/168808.